NexImmune is a biotechnology company advancing antigen-directed immunotherapies. We are developing a novel AIM nanoparticle platform that uses natural biology to orchestrate targeted, cell-mediated immune responses. The same platform can intensify T cell activity to address cancer or infectious disease, or dampen overactive responses in autoimmune conditions.
Latest News
AUGUST 10, 2023
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates
Read More >
JUNE 5, 2023
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial at ASCO 2023
Read More >
FEBRUARY 16, 2023
NexImmune Announces AIM ACT T Cell Data at the 2023 Tandem Meetings
Read More >
T cells are the “foot soldiers” of the immune system.
They identify, engage, and destroy diseased cells throughout the body. Each T cell needs precise instructions to perform that work. In healthy immunity, dendritic cells deliver those signals. When dendritic cells fail in cancer, infection, or autoimmune disease, T cells lose direction and the immune response breaks down. NexImmune’s AIM platform is designed to restore that guidance.
NexImmune “AIMs” to orchestrate cell-mediated immune responses across a range of diseases.
With a focus on patients waiting for better options, our team is advancing immunotherapies built for specificity, potency, and durability rather than incremental change alone.
Our approach centers on T cells as the engine of immune defense. Artificial Immune Modulation (AIM) is a proprietary nanoparticle platform that mimics healthy dendritic cell signaling to activate antigen-specific T cell responses in oncology, autoimmune disorders, and infectious disease.
AIM nanoparticles can be programmed to deliver tailored instructions to defined T cell populations. That precision supports multiple product formats, including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ), each designed to match the biology of the disease being treated.
What You Will Find on This Site
Visitors can explore how the AIM NT platform works, review current and past clinical programs on our pipeline page, and read the dedicated NEXI-001 program overview. Our newsroom links to company announcements, and our technology pages include peer-reviewed abstracts and publications that explain AIM biology in detail.
Whether your interest is T cell engineering, nanoparticle immunology, or clinical development in hematologic malignancies and autoimmune disease, this site is organized to connect each topic to the science, people, and programs that define NexImmune’s work.